Eastwood Bio-Medical: Top 10 Undervalued Retail - Defensive Industry Stocks (EBM)
Eastwood Bio-Medical is now ranked among the top 10 undervalued stocks in the Retail - Defensive industry on the Toronto Stock Exchange or TSX Venture Exchange.
- A stock is considered undervalued if it trades at a discount to its valuation – a calculation used to determine the intrinsic (true) worth of a company
- Valuation methodology provided by Stockcalc (see below)
Retail - Defensive: Companies engaged in the retail sale of a variety of merchandise at low and discounted prices.
Stocks in this category are held primarily for capital appreciation.
| Symbol | Name | Close Price ($) | Valuation ($) | Difference | Average Vol (30D) | Market Cap ($M) | Yield (%) | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
| EBM | Eastwood Bio-Medical | 0.69 | 0.70 | 0.01 (1.0%) | 930 | 47.5 | 0.0 | 0.0 |
All data provided as of April 13, 2024.
The list is sorted by stocks with the greatest percentage difference between valuation and price.
Eastwood Bio-Medical
Eastwood Bio-Medical Canada Inc is a Canadian company engaged in the development and commercialization of safe and effective treatment for non-insulin dependent diabetes mellitus. The company is engaged in natural health supplement distribution company. It has its geographic presence in U.S., Canada and Asia. The company generates maximum revenue from Asia.
Eastwood Bio-Medical is listed under EBM on the TSX Venture Exchange.
Stockcalc
StockCalc is a Canadian fintech company specializing in fundamental valuations for North American stocks and ETFs.
Stockcalc valuations (https://www.stockcalc.com/Resources) can help determine if a stock is undervalued. Stockcalc’s Weighted Average Valuation (WAV) is based on a proprietary calculation using model and analyst inputs, including:
- Discounted Cash Flow (DCF)
- Price & Other Comparables
- Multiples
- Adjusted Book Value (ABV)
- Analyst Consensus
Artificial Intelligence at Report on Business
Report on Business scans market data using algorithms to process large quantities of information. The results are specialized reports produced through automation. Ongoing ROB project experiments that leverage artificial intelligence include valuation screens across 14 categories and end-of-day Closing Summary reports for all North American securities.
